Solabegron
As of the edition of 20 October 2026, Solabegron is a small molecule: went quiet in 2019; acts on ADRB3.
Sources: FDA Orange Book and Purple Book, other approval registers, ClinicalTrials.gov, ChEMBL.
The drug
- Status
- Went quiet, 2019
- Kind
- Small molecule
- Registered trials
- 8, 0 stopped early
- Disease areas
- Pregnancy and women's health; Urinary and reproductive; Digestive system
US protection
No US approval on record.
With no US approval on record there are no listed US patents or exclusivities.
This is the US only.
Companies that need a new molecule because of this drug
1 company on route A because of this drug.
Companies on route A for this drug
In the product1 company is on route A because of Solabegron.
See the 1 company on route A for this drug, with the facts behind eachRequest access. Nothing is shown until you do.
Target
| Gene | Protein | UniProt |
|---|---|---|
| ADRB3 | Beta-3 adrenergic receptor | P13945 |
Registered trials
| Phase | Trials | Completed | Active | Stopped early |
|---|---|---|---|---|
| Phase 1 | 4 | 4 | 0 | 0 |
| Phase 2 | 4 | 4 | 0 | 0 |
| All trials | 8 |
Who ran its trials
| Company | Role | Years |
|---|---|---|
| GSK | Lead sponsor of trials | 2006 to now |
| Velicept Therapeutics | Lead sponsor of trials | 2016 to now |